Olmesartan

  • IUPAC: 5 - (1- hydroxy-1- isopropyl) - 2-propyl -3-[ 2'-( 1H-tetrazol- 5-yl) biphenyl- 4-ylmethyl ] -3H- imidazole-4 -carboxylic acid
  • Latin: Olmesartanum
  • C09CA08
  • C09DA08

Monoclinic crystals ( from ethanol)

Antihypertensive

AT1 antagonist

180-182 ° C ( decomposition)

Practically insoluble in water, slightly soluble in methanol

Template: Infobox chemical / molecular formula search available

Olmesartan medoxomil is a drug from the group of selective AT1 antagonists ( " sartans " ) and is used to treat high blood pressure. Olmesartan medoxomil is a prodrug that is metabolized during absorption from the gastrointestinal tract into the pharmacologically active olmesartan:

A maximum effect is reached after approximately 8 weeks of regular use, while after 2 weeks already, much of the blood pressure reduction is achieved.

Beyond the mere lowering of blood pressure olmesartan, in addition to positive effects on renal function as another therapeutic component has a protective effect on the vessels, as it has anti-atherosclerotic properties.

Areas of application (indications )

Olmesartan is as the newest Sartan since 2002 in Germany for the treatment of high blood pressure in the market. Due to its strong blood pressure reduction and the long-lasting duration of action it offers once daily provided a reliable and consistent regulation of blood pressure.

The antihypertensive effect of olmesartan may be increased by concomitant use of other antihypertensive drugs. For this purpose, often with olmesartan hydrochlorothiazide (HCT ), a diuretic combination.

Contraindications ( contraindications)

Olmesartan may not be taken during pregnancy and lactation as well as in biliary obstruction.

Side effects

Olmesartan is characterized by a very good subjective and objective tolerance. The occurrence of adverse side effects and the adverse event profile was comparable to that of placebo in numerous clinical studies. Be mentioned as side effects of orthostatic hypotension, headache, diarrhea, infections of the upper respiratory tract, increased or decreased heart rate and dry, unproductive cough.

The FDA points out that under Olmesartan diarrhea a celiac similar may occur which is accompanied under certain circumstances, with greater weight loss. The relationship zwischem the blood pressure medicines, and the supposed celiac disease here was not initially clear.

Trade names

Olmetec (A), Olmetec (D, A, CH), vote (D, CH), Belsar

  • In combination with hydrochlorothiazide: Olmetec Plus ( A), Olmetec Plus ( D, A, CH), vote Plus (D, CH), Belsar Plus
  • In combination with amlodipine: Amelior (A), Sevikar (D, A, CH), Vascord (CH), Vocado (D)
  • In combination with amlodipine and hydrochlorothiazide: Amelior HCT (A), Sevikar HCT (D, A, CH), Vocado HCT (D)
CAS registry number PubChem Anatomical Therapeutic Chemical Classification System DrugBank Angiotensin II receptor antagonist Active ingredient
616909
de